Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a pill keep vitiligo at bay? new study aims to find out

NCT ID NCT06163326

Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 27, 2026 · Updated 2 times

Summary

This study tests a daily pill called ritlecitinib in adults and teens with nonsegmental vitiligo, a condition that causes white patches on the skin. The goal is to see if the medicine can maintain or improve skin color regained in a previous study, or if stopping it leads to color loss. About 394 participants who completed a prior year-long study will take the drug or a placebo for up to 52 weeks, with regular checkups to track safety and repigmentation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

394 people

The number who actually took part.

Started

Jan 2024

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants ≥18 years of age at Screening in Study B7981040. Adolescents (12 to \<18 years of age at Screening in the parent study) are also eligible for this study if approved by the local IRB/EC and regulatory health authority. * Participants who met the eligibility criteria and completed 52 weeks of study intervention for stable or active nonsegmental vitiligo in Study B7981040 * The BL visit/first dose in Study B7981041 must be within 30 days after the week 52 visit in Study B7981040 Exclusion Criteria: * Participant met the parent study (Study 7981040) discontinuation criteria or discontinued the parent study for any safety-related event * Any active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-segmental vitiligo are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

generalized vitiligo vitiligo

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Vitiligo

Contacts and locations

Locations

  • AUDIKA

    Córdoba, 14001, Spain

  • Accellacare - Wilmington

    Wilmington, North Carolina, 28411, United States

  • Ajou University Hospital

    Suwon, Kyǒnggi-do, 16499, South Korea

  • Alpesh D. Desai, DO PLLC

    Houston, Texas, 77008, United States

  • Arké SMO S.A de C.V

    Veracruz, 91900, Mexico

  • Austin Institute for Clinical Research

    Houston, Texas, 77056, United States

  • CaRe Clinic

    Red Deer, Alberta, T4P 1K4, Canada

  • California Dermatology & Clinical Research Institute

    Encinitas, California, 92024, United States

  • Celal Bayar University Hafsa Sultan Hospital

    Manisa, 45030, Turkey (Türkiye)

  • Centre de Recherche Dermatologique du Quebec metropolitain

    Québec, G1V 4X7, Canada

  • Centre de Recherche Saint-Louis inc.

    Québec, G1W 4R4, Canada

  • Centro de Dermatologia de Monterrey

    Monterrey, Nuevo León, 64460, Mexico

  • Clinical & Translational Research Center (CTRC)

    Chapel Hill, North Carolina, 27599, United States

  • Dawes Fretzin Clinical Research Group, LLC

    Indianapolis, Indiana, 46250, United States

  • DelRicht Research

    Baton Rouge, Louisiana, 70809, United States

  • DermEdge Research

    Mississauga, Ontario, L4Y 4C5, Canada

  • Dermatology Hospital of Southern Medical University

    Guangzhou, Guangdong, 510091, China

  • Dermatology Research Institute

    Calgary, Alberta, T2J 7E1, Canada

  • Dermatology and Ophthalmology Kume Clinic

    Sakai, Osaka, 593-8324, Japan

  • Dermedic Jacek Zdybski

    Ostrowiec Świętokrzyski, Świętokrzyskie Voivodeship, 27-400, Poland

  • DermoDent Centrum Medyczne Aldona Czajkowska Rafał Czajkowski s.c.

    Osielsko, Kuyavian-Pomeranian Voivodeship, 86-031, Poland

  • Dermoklinika - Centrum Medyczne spółka cywilna M. Kierstan, J. Narbutt, A. Lesiak

    Lodz, Łódź Voivodeship, 90-436, Poland

  • Diagnostic Consultative Center Aleksandrovska

    Sofia, Sofia (stolitsa), 1431, Bulgaria

  • Dr Rodney Sinclair Pty Ltd

    East Melbourne, Victoria, 3002, Australia

  • Encore Medical Research of Boynton Beach

    Boynton Beach, Florida, 33436, United States

  • Erciyes Universitesi Tıp Fakultesi Hastaneleri

    Kayseri, Turkey (Türkiye)

  • Fachklinik Bad Bentheim

    Bad Bentheim, Lower Saxony, 48455, Germany

  • First Affiliated Hospital of Kunming Medical University

    Kunming, Yunnan, 650032, China

  • ForCare Clinical Research

    Tampa, Florida, 33613, United States

  • Guy's & St Thomas' NHS Foundation Trust

    London, SE1 9RT, United Kingdom

  • Hospital Clínic de Barcelona

    Barcelona, Catalunya [cataluña], 08036, Spain

  • Hospital Infantil de Mexico Federico Gomez

    Mexico City, Mexico City, 06720, Mexico

  • Hospital Universitario Ramón y Cajal

    Madrid, Madrid, Comunidad de, 28034, Spain

  • Hospital Universitario Reina Sofia

    Córdoba, Andalusia, 14004, Spain

  • Hospital Universitario de Gran Canaria Doctor Negrín

    Las Palmas de Gran Canaria, LAS Palmas, 35010, Spain

  • Huashan Hospital Fudan University

    Shanghai, Shanghai Municipality, 200040, China

  • Istanbul Universitesi Cerrahpasa

    Istanbul, 34098, Turkey (Türkiye)

  • Lawrence J. Green, MD LLC

    Rockville, Maryland, 20850, United States

  • Lynderm Research Inc.

    Markham, Ontario, L3P 1X3, Canada

  • Marmara Universitesi Pendik Egitim Arastirma Hastanesi

    Istanbul, İ̇stanbul, 34899, Turkey (Türkiye)

  • Marvel Clinical Research

    Huntington Beach, California, 92647, United States

  • Medical Centre "Asklepiy"

    Dupnitsa, Kyustendil, 2600, Bulgaria

  • Medical University of South Carolina

    Charleston, South Carolina, 29425, United States

  • Modern Research Associates, PLLC

    Dallas, Texas, 75231, United States

  • Nagoya City University Hospital

    Nagoya, Aichi-ken, 467-8602, Japan

  • Nippon Medical School Hospital

    Bunkyo-ku, Tokyo, 113-8603, Japan

  • North Eastern Health Specialists

    Campbelltown, South Australia, 5074, Australia

  • North York Research Inc

    Toronto, Ontario, M2N3A6, Canada

  • Praxis Leitz und Kollegen

    Stuttgart, Baden-Wurttemberg, 70178, Germany

  • Remington-Davis, Inc

    Columbus, Ohio, 43215, United States

  • Royalderm Agnieszka Nawrocka

    Warsaw, Masovian Voivodeship, 02-962, Poland

  • SUNY Downstate Health Sciences University

    Brooklyn, New York, 11203, United States

  • Severance Hospital, Yonsei University Health System

    Seoul, Seoul-teukbyeolsi [seoul], 03722, South Korea

  • Skin Care Research

    Hollywood, Florida, 33021, United States

  • Skin Health Institute Inc.

    Carlton, Victoria, 3053, Australia

  • Sociedad de Metabolismo y Corazon S.C.

    Veracruz, 91900, Mexico

  • The Alfred Hospital

    Melbourne, Victoria, 3004, Australia

  • The Catholic University Of Korea St. Vincent's Hospital

    Suwon, Kyǒnggi-do, 16247, South Korea

  • The First Hospital of China Medical University/Dermatology and STD Department

    Shenyang, Liaoning, 110001, China

  • The First Hospital of Wuhan

    Wuhan, Hubei, 430022, China

  • The Skin Hospital

    Darlinghurst, New South Wales, 2010, Australia

  • Tohoku University Hospital

    Sendai, Miyagi, 980-8574, Japan

  • Tokyo Medical University Hospital

    Shinjuku-ku, Tokyo, 160-0023, Japan

  • Twoja Przychodnia SCM

    Szczecin, West Pomeranian Voivodeship, 71-500, Poland

  • UMHAT "Prof. Dr. Stoyan Kirkovich"AD

    Stara Zagora, 6003, Bulgaria

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio, 44106, United States

  • University of Michigan

    Ann Arbor, Michigan, 48109, United States

  • University of New Mexico Health Sciences Center

    Albuquerque, New Mexico, 87102, United States

  • University of North Carolina Medical Center

    Chapel Hill, North Carolina, 27516, United States

  • Universitätsklinikum Münster

    Münster, North Rhine-Westphalia, 48149, Germany

  • Wallace Medical Group, Inc

    Los Angeles, California, 90056, United States

  • Wilmington Health, PLLC

    Wilmington, North Carolina, 28411, United States

  • Yamanashi Prefectural Central Hospital

    Kofu, Yamanashi, 400-8506, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.